![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the exclusive licensing agreement, Oragenics will pursue the development of its lead intranasal COVID-19 vaccine candidate, NT-CoV2-1 (SmT1v3) with Inspirevax’s novel BDX301 intranasal mucosal adjuvant.
Lead Product(s): SmT1v3,BDX301
Therapeutic Area: Infections and Infectious Diseases Product Name: NT-CoV2-1
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Oragenics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 01, 2023